Although sample enrichment can be based on baseline biomarker profiles, there are no studies yet that have systematically addressed which imaging and fluid biomarkers are most strongly associated with longitudinal tau PET at different clinical stages of AD. Here, MAPT is linked to Alzheimer disease.